Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients

Devendra K Hiwase, MBBS, MD PhD FRACP, FRCPA, Deepak Singhal, MD FRCPA,, Rakchha Chhetri, Monika M Kutyna, Peter B Harrison, Shriram V. Nath, FRCPA,DM,MD, Nicholas Wickham, Chi-Hung Hui, James X Gray, MD PhD, David M Ross, MBBS, PhD FRACP, FRCPA, Ian D Lewis, MBBS, PhD, Peter Bardy, John Reynolds, PhD, Luen Bik To, MBBS, PhD

Blood (2014) 124 (21): 1923.

https://doi.org/10.1182/blood.V124.21.1923.1923

Published: 2014

Journal Articles

Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes

Devendra K Hiwase, MBBS, MD PhD FRACP, FRCPA, Chris N Hahn, PhD, Milena Babic, Sarah Moore, BSc(Hon), Carolyn M Butcher, MMedSc(Hons), Monika M Kutyna, Deepak Singhal, MD FRCPA,, Jinghua Feng, Bik To, MD, Andreas Schreiber, PhD, Hamish S Scott, PhD

Blood (2014) 124 (21): 4634.

https://doi.org/10.1182/blood.V124.21.4634.4634

Published: 2014

Journal Articles

High Plasma Levels of TGF-α and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML

Eva Nievergall, PhD, John Reynolds, PhD, Chung H Kok, PhD, Dale Watkins, PhD, Mark Biondo, PhD, Samantha J Busfield, PhD, Gino Vairo, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Angel Lopez, PhD, Devendra K Hiwase, MBBS, MD PhD FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD MBBS, FRACP, FRCPA

Blood (2014) 124 (21): 1788.

https://doi.org/10.1182/blood.V124.21.1788.1788

Published: 2014

Journal Articles

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Lisa Carne, RN, David Ross, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 1503.

https://doi.org/10.1182/blood.V122.21.1503.1503

Published: 2013

Journal Articles

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner

Lisa Schafranek, BSc., (Hons), Eva Nievergall, PhD, Jason A. Powell, BSc, PhD, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Deborah L. White, PhD, FFSc(RCPA), Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, Tamara Leclercq, PhD

Blood (2013) 122 (21): 2705.

https://doi.org/10.1182/blood.V122.21.2705.2705

Published: 2013

Journal Articles

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Monika M Kutyna, Rakchha Chhetri, Stuart Howell, Peter B Harrison, Shriram V Nath, Lakshmi S Nath, Nicholas Wickham, Ferenc Szabo, Chi-Hung Hui, David Ross, James Gray, Junia V Melo, MD, PhD, Peter Bardy, L. Bik To

Blood (2013) 122 (21): 1518.

https://doi.org/10.1182/blood.V122.21.1518.1518

Published: 2013

Journal Articles

Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment

Eva Nievergall, PhD, Deborah L. White, PhD, FFSc(RCPA), Agnes S.M. Yong, MD, PhD, Hayley S. Ramshaw, PhD, Samantha J. Busfield, PhD, Gino Vairo, PhD, Angel F. Lopez, MBBS, PhD, Timothy P. Hughes, MD, MBBS, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA

Blood (2012) 120 (21): 32.

https://doi.org/10.1182/blood.V120.21.32.32

Published: 2012

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity

Lisa Schafranek, BSc., (Hons), Eva Nievergall, PhD, Jason A Powell, PhD, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Deborah L. White, PhD, FFSc(RCPA), Timothy P. Hughes, MD, MBBS

Blood (2012) 120 (21): 3736.

https://doi.org/10.1182/blood.V120.21.3736.3736

Published: 2012

Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA

Blood (2011) 118 (21): 451.

https://doi.org/10.1182/blood.V118.21.451.451

Published: 2011

Journal Articles

Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34 + CML Progenitors to Dasatinib-Induced Cell Death,

Eva Nievergall, Deborah L. White, PhD. FFSc(RCPA), Hayley Ramshaw, PhD, Angel F. Lopez, MBBS, PhD, Timothy P. Hughes, MD, MBBS, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA

Blood (2011) 118 (21): 3745.

https://doi.org/10.1182/blood.V118.21.3745.3745

Published: 2011

Journal Articles

Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?

Annie W.S. Chow, MBBS, Cindy H.S. Lee, MBBS, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Luen Bik To, MBBS, MD, MRCP, FRACP, FRCPA, Noemi Horvath, MB, ChB, FRACP, FRCPA

Blood (2011) 118 (21): 3059.

https://doi.org/10.1182/blood.V118.21.3059.3059

Published: 2011

NARROW

Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients

Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes

High Plasma Levels of TGF-α and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34 + CML Progenitors to Dasatinib-Induced Cell Death,

Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only